BRAFTOVI (encorafenib) is a prescription medication used to treat certain cancers that have spread (metastasized), cannot be removed with surgery, and have specific mutations in the BRAF gene. It is used in the following ways:
  1. Melanoma and Non-Small Cell Lung Cancer (NSCLC): In combination with MEKTOVI (binimetinib), BRAFTOVI is used to treat adults with melanoma or NSCLC that has a BRAF mutation.
  2. Colorectal Cancer (CRC): In combination with cetuximab and mFOLFOX6 (a chemotherapy regimen including fluorouracil, leucovorin, and oxaliplatin) to treat colorectal cancer.
The approval for this combination was based on tumor response and the duration of that response. Ongoing studies are evaluating the clinical benefit of this regimen. Encorafenib may also be used in combination with cetuximab alone for adults with colorectal cancer who have previously received treatment. Important Note: Encorafenib should not be used in people whose melanoma, colorectal cancer, or NSCLC has wild-type BRAF (no mutation). Your healthcare provider will perform a test to confirm if Encorafenib or the combination with binimetinib is appropriate for your condition. BRAFTOVI helps improve tumor response and duration of benefit. When paired with binimetinib or cetuximab-based regimens, it offers powerful, personalized treatment designed to enhance anti-tumor response and extend control. It is not suitable for cancers without the BRAF mutation. It is currently not known whether encorafenib or binimetinib is safe or effective in children. Encorafenib is a BRAF kinase inhibitor targeting mutated BRAF – BRAF V600E, wild-type BRAF, and CRAF, inhibiting tumor growth via the suppression of RAF/MEK/ERK pathway. It also binds other kinases at clinically relevant levels. In combination with binimetinib or cetuximab, it showed enhanced anti-tumor effects and delayed resistance in BRAF-mutant models. Resistance in BRAF-mutant CRC due to EGFR activation can be overcome with EGFR-targeted combination therapy. The drug is marketed globally by Pfizer Inc., and has received FDA approval for use in specific BRAF mutation associated cancers. While Braftovi is available in India, it is generally accessed via named-patient import programs, ensuring legal and safe delivery for patients who need it. By partnering with licensed facilitators such as 24/7QualityMeds, patients can navigate the import process for Braftovi in India with confidence, ensuring safe access to this essential cancer treatment. For individuals with qualifying prescriptions, this pathway offers a vital bridge to advanced therapies that can significantly improve quality of life and treatment outcomes.

Pricing

The Braftovi price in India may vary based on factors such as dosage, duration of therapy, and sourcing channels as well as origin of import and manufacturer supply-chain costs. Patients seeking encorafenib in India are encouraged to request a quotation through authorized facilitators like 24/7QualityMeds, which helps ensure genuine supply and transparent pricing. It is recommended that patients consult their oncologist for exact dosage requirements and obtain a valid prescription before proceeding with the purchase. Costs are finalized after verification of documentation and confirmation of availability through global suppliers.

Access Steps

We assist patients and hospitals in legally importing Braftovi (encorafenib) for medical use. We provide reliable access across major Indian cities. The following steps are required : 
  1. Request for medicine: Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
  2. Verification of documents: The prescription and related medical records are verified to confirm eligibility for importing the drug in small quantities for personal use.
  3. Permission to import: After approval from the Drugs Controller General (India), the process of importing the medicine begins as per the prescription.
  4. Sourcing the medicine: Our sourcing experts connect with global suppliers to find the best available price and confirm availability before finalizing the offer.
  5. Delivery of the medicine: Once approved, the our team arranges shipping and ensures timely and safe delivery of the medicine to the patient.

Documents required:

  1. A doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
  2. Medical history and test reports (preferably from the last three months).
  3. Government-issued identity proof and proof of residence of the patient.
These steps ensure that patients can import and buy encorafenib in India safely, legally, and with full regulatory compliance under the Named Patient Supply (NPS) program.